[{"address1": "Lilly Corporate Center", "city": "Indianapolis", "state": "IN", "zip": "46285", "country": "United States", "phone": "317 276 2000", "website": "https://www.lilly.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "fullTimeEmployees": 43000, "auditRisk": 4, "boardRisk": 4, "compensationRisk": 1, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 885.99, "open": 885.66, "dayLow": 879.8, "dayHigh": 891.97, "regularMarketPreviousClose": 885.99, "regularMarketOpen": 885.66, "regularMarketDayLow": 879.8, "regularMarketDayHigh": 891.97, "dividendRate": 5.2, "dividendYield": 0.0058999998, "exDividendDate": 1715731200, "payoutRatio": 0.6907, "fiveYearAvgDividendYield": 1.4, "beta": 0.363, "trailingPE": 129.79149, "forwardPE": 45.8444, "volume": 3448680, "regularMarketVolume": 3448680, "averageVolume": 2626587, "averageVolume10days": 2865880, "averageDailyVolume10Day": 2865880, "bidSize": 2200, "askSize": 900, "marketCap": 840043986944, "fiftyTwoWeekLow": 434.34, "fiftyTwoWeekHigh": 905.45, "priceToSalesTrailing12Months": 23.37865, "fiftyDayAverage": 794.7036, "twoHundredDayAverage": 681.5015, "trailingAnnualDividendRate": 4.69, "trailingAnnualDividendYield": 0.0052935136, "currency": "USD", "enterpriseValue": 819629522944, "profitMargins": 0.17083, "floatShares": 898208397, "sharesOutstanding": 950404992, "sharesShort": 5400466, "sharesShortPriorMonth": 5535865, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0057, "heldPercentInsiders": 0.00164, "heldPercentInstitutions": 0.83771, "shortRatio": 1.91, "shortPercentOfFloat": 0.0064, "bookValue": 14.229, "priceToBook": 62.11821, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "earningsQuarterlyGrowth": 0.668, "netIncomeToCommon": 6138399744, "trailingEps": 6.81, "forwardEps": 19.28, "pegRatio": 1.03, "lastSplitFactor": "2:1", "lastSplitDate": 876960000, "enterpriseToRevenue": 22.811, "enterpriseToEbitda": 61.287, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "LLY", "underlyingSymbol": "LLY", "shortName": "Eli Lilly and Company", "longName": "Eli Lilly and Company", "firstTradeDateEpochUtc": 76253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 883.88, "targetHighPrice": 1023.0, "targetLowPrice": 600.0, "targetMeanPrice": 863.79, "targetMedianPrice": 875.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 25, "totalCash": 2652499968, "totalCashPerShare": 2.946, "ebitda": 13373700096, "totalDebt": 26346500096, "quickRatio": 0.674, "currentRatio": 1.354, "totalRevenue": 35932098560, "debtToEquity": 204.278, "revenuePerShare": 39.919, "returnOnAssets": 0.12604, "returnOnEquity": 0.50747, "freeCashflow": -1232225024, "operatingCashflow": 3675500032, "earningsGrowth": 0.664, "revenueGrowth": 0.26, "grossMargins": 0.80160004, "ebitdaMargins": 0.37219003, "operatingMargins": 0.312, "financialCurrency": "USD", "trailingPegRatio": 2.6139, "__fetch_time": "2024-06-24"}]